The double-blind, randomized study, led by principal investigator Tomasz Beer, M.D., recently was published in the journal Cancer.* Beer is the Grover C. Bagby Endowed Chair for Cancer Research, director of the OHSU Cancer Institute Prostate Cancer Program, and associate professor of medicine (hematology/medical oncology), OHSU School of Medicine.

Beer and his team wanted to know if men with metastatic, androgen-independent prostate cancer cancer that has spread from the prostate and is not affected by the male hormone, androgen could take a break from docetaxel, an intravenous chemotherapy delivery drug that is the gold standard treatment for androgen-independent prostate cancer. Docetaxel works by killing cancer cells and slowing cell growth. However, the drug also can cause side effects, such as hair loss, nausea, loss of appetite and increased chance for infections. Chemo holidays can be a much-needed vacation from these side effects.

Prior to this study, it wasn't known whether stopping chemotherapy would lead to treatment resistance.

"We wanted to see if we could improve the quality of life for these patients by giving them time away from chemotherapy and possibly extend the time their cancer is controlled. Essentially, what we proved is that in selected subjects, chemotherapy holidays are feasible and provided meaningful breaks from treatment," said Beer.

This is the first multi-institutional trial to examine outcomes from intermittent chemotherapy. A total of 250 men participated. Of those, 18 percent entered the intermittent arm of the study. These men previously had responded well to chemotherapy.

The median duration of the first chemo holiday was 18 weeks. On resumption of chemotherapy, it the majority of subjects responded to treatment. Specifically, 45.5 percent of participants responded with a greater than 50 percent reduction in prostate specific antigen (PSA) from their post-holiday baseline; of those, 45.5 percent had stable PSAs for at least 12 weeks; and 9.1 percent developed disease progression. Prostate-specific antigen is a protein produced by the cells of the prostate gland and is present in small quantities in the serum of healthy men, and it often elevates when prostate cancer is present. Most men have less than 4 nanograms. Anything higher can indicate prostate cancer.

The next step, said Beer, is to study the addition of immunotherapy, treating the cancer by working with the immune system, during the chemotherapy holidays.

"Because we know holidays are a good thing, we want to find ways to make them even longer," Beer said. OHSU and Beer have significant financial interest in Novacea, Inc., a company that has a commercial interest in the results of this research and technology. This potential conflict was reviewed and a management plan approved by the OHSU Conflict of Interest in Research Committee and the Integrity Program Oversight Council was implemented.

Other authors include: Christopher Ryan, M.D., Division of Hematology/Medical Oncology OHSU Cancer Institute, OHSU School of Medicine; Peter Venner, M.D., Cross Cancer Institute, Alberta Cancer Board, Alberta, Canada; Daniel Petrylak, M.D., Division of Hematology and Medical Oncology, Columbia Presbyterian Medical Center, New York; Gurkamal Chatta, M.D., Pavillion Hellman Cancer Center, University of Pittsburgh; J. Dean Ruether, M.D., Tom Baker Cancer Centre, Alberta Cancer Board, Calgary, Alberta, Canada; Kim Chi, M.D., Division of Medical Oncology, University of British Columbia, Cancer Agency -- Vancouver Centre, Vancouver, British Columbia, Canada; James Young, M.S., and W. David Henner, M.D., Ph.D., Novacea Inc., San Francisco.

*The study is titled: "Intermittent Chemotherapy in Patients With Metastatic Androgen-Independent Prostate Cancer.

Note: If no author is given, the source is cited instead.

• Prostate Cancer
• Men's Health
• Lung Cancer
• Colon Cancer
• Breast Cancer
• Urology

• Metastasis
• Nanomedicine
• Tumor suppressor gene
• Urology
• Glioma
• Carcinogen